Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

Table 1

Characteristics of the included trials.

Trial	Author and year	Country	Number	Regimens	Follow-up (month)	Randomization	Blind	Allocation concealment	Withdrawal and dropout	ITT	Jadad score
VISTA; NCT00111319	San Miguel et al. 2008, 2010, 2013 [10–12]	Europe, America, Asia	682	E: VMP 9 cyc; C: MP 9 cyc	60	Yes	No	Unclear	Yes	Yes	3
IFM2005-01; NCT00200681	Harousseau et al. 2010 [13]	France, Belgium, Switzerland	482	E: VAD 4 cyc ± DCEP + ASCT; C: BD 4 cyc ± DCEP + ASCT	32.2	Yes	No	Unclear	Yes	Yes	3
MM-BO2005; NCT01134484	Cavo et al. 2010, 2012 [14, 15]	Italy	474	E: VTD 3 cyc + ASCT + VTD 3 cyc; C: TD 3 cyc + ASCT + TD 3 cyc	36	Yes	No	Yes	Yes	Yes	4
PETHEMA/GEM; NCT00461747	Rosiñol et al. 2012 [16]	Spain	257	E: VTD 6 cyc + ASCT + T; C: TD 6 cyc + ASCT + T	56.2	Yes	No	Unclear	Yes	Yes	3
HOVON-65/GMMG-HD4; ISRCTN:64455289	Sonneveld et al. 2012 [17]	Germany, Netherlands, Belgium	827	E: PAD 3 cyc + ASCT + P; C: VAD 3 cyc + ASCT + T	41	Yes	No	No	Yes	Yes	3
THAL-MM-003; NCT00057564	Rajkumar et al. 2008 [18]	Australia, Spain, America	570	E: TD; C: placebo + D; (until progression)	22.6	Yes	Yes	Yes	Yes	Yes	5
IFM01/01; NCT00644306	Hulin et al. 2009 [19]	Belgium	229	E: MPT 12 cyc; C:   MP 12 cyc	47.5	Yes	No	Unclear	Yes	Yes	3
HOVON49; ISRCTN:90692740	Wijermans et al. 2010 [20]	Netherlands	333	E: MPT 8 cyc; C: MP 8 cyc	48	Yes	No	Unclear	Yes	Yes	3
GISMM2001-A; NCT00232934	Palumbo et al. 2006, 2008 [21, 22]	Italy	255	E: MP 6 cyc + T; C: MP 6 cyc	38.4	Yes	No	Yes	Yes	Yes	5
IFM99-06; NCT00367185	Facon et al. 2007 [23]	France, Belgium, Switzerland	321	E: MPT 12 cyc; C: MP 12 cyc	51.5	Yes	No	Unclear	Yes	Yes	3
NMSG#12; NCT00218855	Waage et al. 2010 [24]	Norway, Sweden, Denmark	357	E:  MPT; C:  MP; (until plateau phase)	42	Yes	Yes	Unclear	Yes	Yes	5
UARK98-026; NCT00083551	Barlogie et al. 2006, 2008 [25, 26]	America	668	E: total therapy 2 + T; C: total therapy 2	96	Yes	No	Unclear	Yes	Yes	3
HOVON-5-/GMMG-HD3; ISRCTN:06413384	Lokhorst et al. 2008, 2010 [27, 28]	Netherlands, Germany, Belgium	556	E: VAD; C: TAD	52	Yes	No	Unclear	Yes	Yes	3
TMSG-2005-001; NCT00934154	Beksac et al. 2011 [29]	Turkey	115	E: MPT 8 cyc; C: MP 8 cyc	23	Yes	No	Unclear	No	Yes	2
MM03; NCT01274403	Sacchi et al. 2011 [30]	Italy	118	E: MPT 6–12 cyc; C: MP 6–12 cyc	30	Yes	No	Unclear	Yes	Yes	3
SO232; NCT00064038	Zonder et al. 2010 [31]	America	192	E: LEX + DEX; C: placebo + DEX; (until progression)	47.2	Yes	Yes	Unclear	Yes	Yes	5
MM-015; NCT00405756	Palumbo et al. 2012 [32]	Europe, Australia, Israel	306	E: MPR 9 cyc + R; C: (placebo + MP) 9 cyc	30	Yes	Yes	Unclear	Yes	Yes	5

E: experiment arm; C: control arm; cyc: cycles; VMP: bortezomib, melphalan; MP: melphalan, prednisolone; VAD: vincristine, adriamycin, and dexamethasone; prednisolone; DCEP: dexamethasone, cyclophosphamide, etoposide, and cisplatin; BD: bortezomib, dexamethasone; VTD: bortezomib, thalidomide, and dexamethasone; TD: thalidomide, dexamethasone; PAD: bortezomib, adriamycin, and dexamethasone; MPT: melphalan, prednisolone, and thalidomide; R: lenalidomide.